Nippon Shinyaku Co Ltd
TSE:4516
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Activision Blizzard Inc
XETRA:AIY
|
US |
|
IAR Systems Group AB
STO:IAR B
|
SE |
Nippon Shinyaku Co Ltd
Total Current Assets
Nippon Shinyaku Co Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nippon Shinyaku Co Ltd
TSE:4516
|
Total Current Assets
¥171.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Total Current Assets
¥3.1T
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Total Current Assets
¥2.1T
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
6%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Total Current Assets
¥1.6T
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Total Current Assets
¥1.7T
|
CAGR 3-Years
9%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Total Current Assets
¥1.4T
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
|
Nippon Shinyaku Co Ltd
Glance View
Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.
See Also
What is Nippon Shinyaku Co Ltd's Total Current Assets?
Total Current Assets
171.5B
JPY
Based on the financial report for Dec 31, 2025, Nippon Shinyaku Co Ltd's Total Current Assets amounts to 171.5B JPY.
What is Nippon Shinyaku Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
8%
Over the last year, the Total Current Assets growth was 6%. The average annual Total Current Assets growth rates for Nippon Shinyaku Co Ltd have been 3% over the past three years , 6% over the past five years , and 8% over the past ten years .